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of collagen fibers. It plays the largest role in attaching the 
tooth to the alveolar socket  [1] . Studies by Slavkin and 
Boyde  [2] and Slavkin  [3] have shown that proteins, se-
creted during tooth development by the Hertwig root 
sheath, play a crucial role in the formation of acellular 
root cementum. These proteins, referred to as enamel 
matrix proteins, constitute the largest proportion of the 
enamel matrix  [1, 4] . They consist of a whole family of 
proteins, of which 90%  are amelogenins, and the remain-
ing 10% prolin-rich nonamelogenins, tuftelin and other 
serum proteins  [4] . It has been shown that during evolu-
tion, the chemical structure of amelogenin has remained 
more or less constant, even among the individual animal 
species, exhibiting only slight differences  [4] . In a series 
of animal experiments on root development in rats, mon-
keys and pigs, it was immunohistologically demonstrated 
that the concentration of amelogenin rises dramatically 
during tooth development  [1] . Also, a close connection 
between acellular cementum and amelogenin exists  [1] . 
These findings have also been confirmed in human teeth, 
where some histological sections showed a thin layer of 
highly mineralized enamel between dentin and root ce-
ment. These observations permit the assumption that the 
attachment of enamel matrix must occur on the dentin 
surface before the emergence of acellular cementum  [1] . 
Based on such evidence, several in vivo experiments in 
animal models were conducted  [1] . In an experiment, the 
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 Abstract 
 Regenerative periodontal therapy aims at reconstitution of 
the lost periodontal structures such as new formation of root 
cementum, periodontal ligament and alveolar bone. Find-
ings from basic research indicate that enamel matrix protein 
derivative (EMD) has a key role in periodontal wound heal-
ing. Histological results from animal and human studies 
have shown that treatment with EMD promotes periodontal 
regeneration. Moreover, clinical studies have indicated that 
treatment with EMD positively influences periodontal 
wound healing in humans. This review aims to present an 
overview of evidence-based clinical indications for regen-
erative therapy with EMD. 
 
Copyright © 2007 S. Karger AG, Basel
 
 Introduction 
 Results from basic research indicate the role of the dif-
ferent types of cementum for attaching the tooth and re-
parative processes in the entire periodontium. Acellular 
cementum is the most important tissue for the insertion 
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lateral incisors of 2 monkeys were extracted and stan-
dardized cavities in the root surface were created, mesi-
ally and distally. The test cavities were then filled with an 
enamel matrix derivative (EMD), while the control cavi-
ties remained untreated. All the teeth were reimplanted 
into their original alveoles. Histological evaluation 8 
weeks after reimplantation showed formation of acellular 
cementum in the defects in which EMD had been ap-
plied, but in the untreated control defects, only a repara-
tive, cellular cementum developed  [1] . On the basis of 
these findings, the EMD from the tooth pouches of un-
erupted teeth of young pigs was isolated, purified and 
lyophilized. Since EMD is highly hydrophobic, it was sol-
ubilized by interaction with PGA carrier, prior to using it 
for regenerative periodontal therapy  [5] . Maycock et al. 
 [6] identified enamel matrix proteins and proteolytic en-
zymes present in EMD and compared them with those 
extracted from developing porcine enamel. The results 
have shown that while developing enamel contained am-
elogenins, albumin, amelin and enamelin, EMD con-
tained only amelogenins. Thus, for the time being, it may 
be assumed that the main component of EMD are amelo-
genins  [4–6] . A technique or a material must, however, 
fulfill the following criteria in order to be classified as 
‘regeneration-promoting’  [7] :
 • in vitro studies, which confirm the action mecha-
nism; 
 • controlled histological animal studies, which demon-
strate formation of new root cementum, periodontal 
ligament (PDL) and alveolar bone; 
 • human biopsies, which show formation of root cemen-
tum, PDL and alveolar bone on a plaque-infected root 
surface; 
 • controlled clinical studies, which prove a gain of clin-
ical attachment and radiological new bone forma-
tion. 
 In the following overview, the existing evidence re-
garding the clinical use of EMD is provided.
 In vitro Studies 
 Several in vitro investigations have been carried out to 
study the mechanism of EMD on the PDL, gingival fibro-
blast and bone cells  [8–40] . In a series of laboratory stud-
ies, the effect of EMD on migration, attaching, prolifera-
tion, biosynthesis activity and formation of mineralized 
nodules was examined. Immunoassays were performed 
to determine the possible presence of existing polypep-
tide factors  [5, 8] . The results showed that under in vitro 
conditions EMD promotes (a) the proliferation of PDL 
fibroblasts but not epithelial cells, (b) increased total pro-
tein synthesis of the PDL fibroblasts, and (c) the forma-
tion of mineralized nodules by PDL fibroblasts. In the 
above-mentioned studies no specific molecules such as 
IGF-1 and 2, PDGF BB, TNF, TGF-  or IL-1  could be 
identified. PDL fibroblasts treated with EMD displayed 
an increased intracellular cAMP concentration and au-
tocrine releasing of TGF-  1, IL-6 and PDGF AB com-
pared to the control group (without EMD)  [12] . Although 
the epithelial cells showed an increased release of cAMP 
and PDGF AB, following the additional application of 
EMD, their proliferation and growth rates were inhibited 
 [10, 12] . It was concluded that EMD simultaneously pro-
motes the growth of mesenchymal cells by inhibiting that 
of the epithelial cells and the release of autocrine growth 
factors from PDL fibroblasts  [12] . Similar findings were 
also reported by Okubo et al.  [13] , who demonstrated that 
EMD has no appreciable effect on osteoblastic differen-
tiation, although it stimulates cell growth, and IGF-1 and 
TGF-  1 production in PDL cells.
 Palioto et al.  [14] evaluated the effect of EMD, IGF-1 
and the combination of these 2 factors on the prolifera-
tion, adhesion, migration and expression of type I colla-
gen in PDL fibroblasts. The results indicated that the pro-
liferation of PDL fibroblasts was significantly stimulated 
both by EMD and EMD plus IGF-1, in a dose- and time-
dependent manner. However, these factors did not affect 
the adhesion, migration or expression of type I collagen 
of these cells. Other data indicate that EMD may contain 
additional mitogenic factors such as TGF-  and BMP-
like growth factors that stimulate fibroblastic prolifera-
tion and contribute to the induction of biomineralization 
during periodontal regeneration  [15–18] .
 Keila et al.  [19] investigated the effects of EMD on rat 
bone marrow stromal cells and on gingival fibroblasts. 
EMD increased the osteogenic capacity of bone marrow 
and mineralized nodule formation. The presence of EMD 
in the initial stages (first 48 h) of the culture was crucial 
for this effect. In contrast, EMD did not induce osteoblas-
tic differentiation of gingival fibroblast but increased up 
to 2-fold both in numbers and the amount of matrix pro-
duced. In further investigations, it was shown that the 
attaching, growth and metabolic rate of PDL fibroblasts 
increased significantly when EMD was added in cell cul-
tures and that EMD may convert the differentiation path-
way of pluripotent C2C12 mesenchymal cells into osteo-
blast and/or chondroblast lineage  [8–10, 12, 20] . PDL fi-
broblasts showed a significantly increased alkaline 
phosphatase activity following the application of EMD 
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and it enhanced human PDL fibroblast proliferation  [21, 
22] . In the presence of EMD, human PDL fibroblasts 
showed some morphological changes that made them 
more similar to cementoblasts than to fibroblasts, sug-
gesting a process of cellular differentiation  [22] . A recent 
study examined the influence of EMD on the viability, 
proliferation and attachment of periodontal fibroblasts to 
diseased root surfaces  [23] . The results indicated that cell 
viability was negatively affected for higher doses over 
time, while low doses displayed viability effects similar to 
those of the control. PDL cell proliferation appeared to be 
ameliorated following exposure to EMD and the scan-
ning electron microscopy analysis suggested that cellular 
attachment to diseased dentin was enhanced following 
EMD application. Further investigations demonstrated 
that EMD significantly increased the mRNA synthesis of 
the matrix proteins versican, biglycan and decorin and 
led to an increased hyaluronan synthesis in the gingival 
and desmodontal fibroblasts  [9] . It was also suggested 
that integrins are involved in the interaction of PDL and 
gingival fibroblasts with EMD  [24] . However, it has to be 
emphasized that in most studies, EMD had a stronger ef-
fect on desmodontal than on gingival fibroblasts. Other 
experimental investigations have shown that the applica-
tion of EMD can regulate the expression of the genes as-
sociated with cementoblasts, which, in turn crucially af-
fects the mineralization process  [25] . Inoue et al.  [26] 
evaluated whether or not the application of EMD to dif-
ferent dental materials (which do not normally support 
cementogenesis such as gutta percha, calcium hydroxide, 
amalgam and super EBA cement) would alter the in vitro 
phenotype of PDL cells. Their findings indicated that 
EMD can alter the phenotype of PDL cells when cultured 
on these materials. However, some studies have failed to 
show an influence of EMD upon the proliferation of 
mouse fibroblasts and marrow stromal cells  [27] . Very 
recent data have shown that neither EMD nor PGA has 
the ability to induce hard tissue and that enamel matrix 
proteins contained within EMD might aggregate on the 
dentin surface and inhibit the effect of the demineralized 
dentin matrix  [28] . In a study investigating clot adhesion 
to protein-conditioned root surfaces, human dentin 
blocks were exposed to either a saturated citric acid solu-
tion or a commercial ethylenediaminetetraacetic acid 
(EDTA) preparation using standardized protocols  [29] . 
Some dentin blocks were additionally conditioned with 
either bovine serum albumin (BSA) or EMD. Subse-
quently, fresh human whole blood was applied to the 
blocks and the blood was allowed to clot before rinsing in 
phosphate-buffered saline to test adhesion by means of 
scanning electron microscopy. The results indicated that 
EDTA appeared less efficacious than citric acid in remov-
ing the smear layer and in exposing dentin tubules and 
collagen. Fibrin clot adhesion was best supported by the 
citric-acid-treated dentin surface, whereas forces pro-
duced by the rinse protocol partially removed the fibrin 
clot from EDTA-treated root surfaces. The results also 
indicated that BSA- or EMD-treated surfaces poorly re-
tained the fibrin clot and produced a surface morphology 
similar to that of the smear layer.
 Kawase et al.  [30] examined the effect of EMD on the 
proliferation of oral epithelial cells (SCC25). After 3 days 
of treatment with EMD, cell division was prevented and 
at the same time the cell cycle was stopped in the G1 
phase. Furthernore, it was shown that the addition of 
EMD significantly limited the expression of cytokeratin-
18. The authors concluded that EMD does not possess a 
cytostatic but, rather, a cytotoxic effect on epithelial cells 
 [30] . In an in vitro study, the combination of 4 mg EMD 
and active demineralized freeze-dried allogenic bone 
showed an increased bone induction  [31] . It was conclud-
ed that EMD possesses not osteoinductive but osteopro-
motive characteristics when applied at certain concentra-
tions  [31] . Schwarz et al.  [32] have shown that EMD stim-
ulates the early stages of the osteoblast maturation by 
increasing cell proliferation. However, when applied to 
mature cell lines, the main effect was confined to influ-
encing cell differentiation. A stimulatory role of EMD on 
mineralized tissue formation by modulating regulatory 
molecules, critical to bone metabolism at the RNA level, 
has also been reported  [33] .
 Schwarz et al.  [34] investigated the effects of EMD on 
attachment, proliferation and viability of human SaOs 2  
osteoblasts on titanium implants. The results indicated 
that EMD-enhanced cell proliferation and viability of hu-
man SaOs 2  osteoblasts on sandblasted/acid-etched (SLA) 
titanium implants are concentration-dependent. Treat-
ment of osteoblasts with EMD significantly stimulated 
cell proliferation and fibroblast growth factor-2 expres-
sion but decreased alkaline phosphatase expression  [35] . 
It was also suggested that EMD may elicit its mitogenic 
signal through an EMD-specific receptor tyrosine kinase 
towards extracellular signal-regulated kinase 1/2  [36] . It 
seems that EMD treatment may enhance the cellular ac-
tivities of osteoblasts and osteoclasts, which in turn might 
support the regeneration of periodontal bony defects  [37] . 
Since soluble peptides released from EMD may contribute 
to the stimulating effects on cell proliferation, a direct 
contact between EMD and osteoblasts might not be re-
quired to induce cell proliferation  [38] . Shimizu et al.  [39] 
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examined the ability of EMD to regulate bone sialoprotein 
gene transcription in osteoblast-like cells. The findings 
identified EMD response elements in the rat bone sialo-
protein gene promoter that may mediate the effects of 
EMD on bone sialoprotein gene transcription.
 A very recent study evaluated the effect of a combina-
tion of a bioactive glass and EMD upon the proliferation 
and differentiation of the mouse preosteoblastic cell line 
MC3T3-E1  [40] . Cells were cultured up to 28 days in con-
tact with 3 types of granule: Bioglass 45S5 granules, 45S5 
granules coated with EMD and a less reactive glass used 
as a control (60S). The results indicated that both Bioglass 
45S5 granules alone or coated with EMD have the ability 
to support the growth of osteoblast-like cells in vitro and 
promote osteoblast differentiation by stimulating the ex-
pression of major phenotypic markers. However, the bio-
active granules coated with EMD revealed significantly 
higher protein production than the bioactive granules 
alone.
 Parkar and Tonetti  [41] evaluated the selective effects 
of EMD on the activities of 268 cytokine, growth factor 
and receptor genes in PDL. The results indicated that 46% 
(125 of 268) of the tested genes were found to be expressed 
by the PDL cells. Of these 125 genes, 38 were differential-
ly expressed by PDL cells cultured in the presence of EMD. 
Of the 38 genes, 12 most notably inflammatory genes were 
found to be downregulated, whereas 26 genes, many cod-
ed for growth factors and growth factor receptors, dem-
onstrated upregulation, The results indicated that EMD 
downregulates the expression of genes involved in the ear-
ly inflammatory phases of wound healing while simulta-
neously upregulating genes encoding growth- and repair-
promoting molecules.
 It is important to note that certain antibacterial effects 
and disturbances of bacterial adherence were also found 
to be influenced by EMD  [42–47] . Plaque samples (from 
24 patients with periodontitis) that were allowed to accu-
mulate for 4 days were taken and divided into 5 equal 
parts afterwards  [42] . Each part was mixed with 5   l of 
one of the following solutions: NaCl, EMD in water, EMD 
in PGA vehicle, PGA vehicle and chlorhexidine digluco-
nate. Subsequently, vital fluorescent microscopy was used 
to evaluate the vitality of the plaque flora. The results 
showed that EMD in the PGA vehicle had a very strong 
antibacterial effect. It was concluded that the antibacte-
rial effect of EMD is mainly due to the effect of the PGA 
carrier. These findings were later confirmed in an observ-
er-blind, randomized 5-cell crossover study, demonstrat-
ing for the first time a direct influence of EMD on the 
vitality of supragingival dental plaque in vivo  [43] . In a 
further investigation, it was shown that EMD inhibits the 
growth of the periodontal pathogenic bacteria  Actinoba-
cillus actinomycetemcomitans ,  Porphyromonas gingivalis 
and  Prevotella intermedia.  Twenty-four hours following 
the application of EMD no living colonies of these patho-
genic bacteria could be observed. Moreover, EMD dem-
onstrated no negative effect on Gram-positive bacteria 
 [44] . The inhibitory effect of EMD on periodontal patho-
genic bacteria was also confirmed by others  [45, 46] . Re-
cent data also suggest that  P. gingivalis diminishes the ef-
fect of EMD on PDL cells in vitro through a cooperative 
action of gingipains  [47] . Rincon et al.  [48] evaluated the 
influence of EMD on cultured gingival, PDL and dermal 
fibroblasts, using an in vitro model of wound healing. It 
demonstrated that cells in vitro fill an empty space by a 
combination of proliferation and cell migration, thus in-
dicating that EMD may exert an influence on cells in-
volved in wound healing. In a study in rabbits Mirastsch-
ijski et al.  [49] primarily investigated the in vivo effects of 
EMD on skin wound healing. Secondly, they examined 
the in vitro effects of EMD on dermal fibroblasts and mi-
crovascular endothelial cells. Full-thickness, circular 2-
cm skin wounds in white 16-week-old rabbits were treated 
3 times a week with EMD (30 mg/ml) in the vehicle PGA 
and the vehicle alone acted as control. EMD treatment 
increased the amount of granulation tissue and acceler-
ated the time to complete epithelialization by 3 days, com-
pared to the vehicle treatment. In cultured fibroblasts, 
vascular endothelial growth factor levels in conditioned 
media were increased more than 5-fold with EMD treat-
ment over control, as measured by specific enzyme-linked 
immunosorbent assay. EMD also increased the release of 
matrix metalloproteinase-2 from fibroblasts and endo-
thelial cells more than 3-fold. It was concluded that EMD 
significantly accelerated wound closure in rabbits, possi-
bly by increasing the levels of growth factors and protein-
ases important for granulation tissue formation and gran-
ulation. It was shown that EMD may express some angio-
genetic effects which may play an important role in early 
wound healing  [50] . Recent results pointed to the anti-in-
flammatory properties of EMD which attenuated the re-
lease of TNF-  and IL-8 in whole blood from healthy do-
nors, challenged by lipopolysaccharide or peptidoglycan 
 [51] . Furthermore, it was shown that EMD inhibits the at-
tachment of a typical breast cancer cell line (MCF-7) to a 
bone matrix, thus suggesting that EMD might be useful 
as an antiadhesive agent for breast cancer cells to bone in 
vivo  [52] .
 In conclusion, the data from in vitro studies strongly 
indicate that EMD affects important wound healing 
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mechanisms. However, to date, it appears that the under-
lying molecules and mechanisms are still not completely 
understood.
 Controlled Histological Studies in Animals 
 In an experimental study in rats the effects and distri-
bution of EMD in the periodontal tissues of maxillary rat 
molars transplanted to a subcutaneous position in the ab-
dominal wall were studied  [53] . Molars were transplant-
ed with or without EMD, either immediately after extrac-
tion or after drying for 30 min. The rats were killed after 
2 days or 1, 2 or 4 weeks and the teeth were examined by 
light microscopy and immunohistochemistry with anti-
amelogenin antibodies. The teeth that were transplanted 
immediately after extraction showed formation of alveo-
lar bone separated from the dental roots by a periodontal 
space, regardless of the use of EMD. New alveolar bone 
was formed in 5 out of 8 teeth after 2 and 4 weeks in the 
teeth transplanted with EMD after drying for 30 min. 
None of the teeth transplanted without EMD showed al-
veolar bone formation. Additionally 1 tooth transplanted 
with EMD showed root resorption after drying, while re-
sorption was noted in all teeth transplanted without 
EMD. EMD was detected as early as 2 days on all the teeth 
transplanted with EMD and was still demonstrable after 
4 weeks. In experimental dogs, it was shown that the ap-
plication of EMD in intrabony defects may significantly 
stimulate the proliferation of PDL cells  [54] . However, 
this effect was limited to the first 4 weeks following sur-
gery, thus indicating that the main effect of EMD is lim-
ited to the early stage of periodontal wound healing. In 
another study defects were filled with either vehicle (con-
trol) or EMD (test) in rat periodontal window wounds, 
with no microbial biofilm or epithelial downgrowth  [55] . 
The animals were sacrificed 7, 14 and 21 days after wound-
ing. Specimens of periodontium were immunostained for 
osteopontin, bone sialoprotein and osteocalcin as mark-
ers of osteogenic differentiation and for   -smooth muscle 
actin, a myofibroblastic marker. The results indicated 
that EMD did not appear to affect the expression of dif-
ferentiation markers or bone matrix protein synthesis in 
the repopulation response of wounded rat molar peri-
odontium. It was suggested that the effect of EMD on 
wound healing in the periodontium may be independent 
of differentiation in the cell populations examined in the 
type of model used  [55] .
 In a controlled histological study, recession defects 
were created and treated with EMD  [56] . Standardized 
defects were created, by surgically removing the entire 
buccal bone plate and the root cementum. The test de-
fects were treated with EMD, while in the control defects 
a coronally repositioned flap was made. Eight weeks after 
surgery the animals were sacrificed and the appropriate 
jaw segments histologically evaluated. The results showed 
that in all test defects a new periodontium (acellular ce-
mentum with inserting collagen fibers and new alveolar 
bone) developed. In the control defects, the healing was 
characterized by a long junctional epithelium with very 
limited cementum and new bone formation. If in the con-
trol defects new cementum was formed, it was mostly cel-
lular and only partly attached at the root surface. Inter-
estingly, in this study, in the test defects no root resorp-
tion occurred, but in the control defects, root resorption 
was a very frequent phenomenon. It is important to note 
that during the entire study period no oral hygiene mea-
sures were carried out. In an experimental study in mon-
keys acute fenestration-type defects were surgically cre-
ated and subsequently treated with (a) guided tissue re-
generation (GTR), (b) EMD or (c) coronally repositioned 
flaps (control)  [57] . All 3 treatment approaches enhanced 
the formation of new connective tissue attachment and 
new bone, but there was no major difference between the 
treatment groups. The results also indicated that acute 
fenestration-type defects do not seem to be the suitable 
test model for determining the potential of any type of 
regenerative approach  [57] . In 2 subsequent studies in 
monkeys, recession-type and intrabony defects were sur-
gically created and exposed to dental plaque infection 
 [58, 59] . Following initial periodontal therapy consisting 
of oral hygiene measures and topical application of 
chlorhexidine, the defects were treated with 1 of the fol-
lowing therapies: (a) GTR, (b) EMD, (c) EMD + GTR or 
(d) open flap debridement surgery (control). Histological 
investigation showed healing in the control defects, char-
acterized by a long junctional epithelium and a limited 
periodontal regeneration. Treatment with GTR, EMD or 
EMD + GTR resulted in the formation of cementum with 
inserting collagen fibers as well as of alveolar bone  [58, 
59] . Comparable results were also reported in rat, dog and 
monkey defects, with either spontaneous intrabony and 
experimentally created intrabony, recession or dehis-
cence-type defects  [60–64] . A histomorphometrical 
study in dogs evaluated the effectiveness of EMD to in-
duce regeneration of periodontal tissues in class II furca-
tion lesions with or without GTR  [65] . Experimental class 
II furcations were made in the premolars of 4 dogs. The 
furcation defects were filled with gutta percha to induce 
an inflammatory response and to prevent spontaneous 
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repair. Twenty-one days later, the defects were treated 
with (a) GTR, (b) EMD or (c) open flap debridement sur-
gery (control). Histological analysis at 8 weeks following 
therapy showed healing characterized by formation of a 
long junctional epithelium and limited bone formation in 
the control group. Treatment with EMD led to significant 
regeneration of the furcation lesions but association with 
membranes was detrimental. Another study, using mon-
keys, histologically evaluated the healing of mandibular 
class III furcation defects following treatment with (a) 
GTR, (b) EMD, (c) EMD + GTR or (d) open flap debride-
ment surgery (control)  [66] . The results showed that 
treatment with GTR or EMD + GTR resulted in forma-
tion of new cementum with inserting collagen fibers, and 
new bone was filling the defects in the situation where the 
membrane was not exposed. The sites treated only with 
EMD exhibited new attachment and new bone formation 
to a varying extent, while the control sites presented only 
limited new attachment and bone formation.
 In conclusion, animal data indicate that EMD is pres-
ent on the treated root surfaces for a period of at least 4 
weeks and predictably it promotes formation of cemen-
tum, PDL and bone in fenestration, recession, intrabony 
and mandibular class II furcation defects.
 Human Histological Studies 
 Results of the first human histological biopsy were 
published by Heijl  [67] . A recession defect on a lower inci-
sor was surgically created and treated with EMD. After a 
healing period of 4 months, histological evaluation of the 
tooth as well as the surrounding soft- and hard-tissue ex-
tracts showed that a new layer of acellular root cementum 
covered 73% of the original defect depth. New alveolar 
bone had regenerated on 65% of the initial bone height. In 
another study Yukna and Mellonig  [68] treated 10 intra-
bony periodontal defects in 8 patients with EMD. Histo-
logical analysis 6 months later showed complete peri-
odontal regeneration (i.e. new formation of root cemen-
tum, PDL and alveolar bone) in 3 biopsies and 3 further 
biopsies indicated healing characterized by a new connec-
tive tissue attachment (i.e. new cementum with inserting 
collagen fibers). The remaining 4 biopsies showed a long 
junctional epithelium without any signs of periodontal re-
generation. In a comparative clinical and histological in-
vestigation, the healing of intrabony periodontal defects 
was evaluated following treatment with EMD or GTR 
with a bioabsorbable barrier  [69] . Six months after thera-
py, clinical attachment level (CAL) showed a mean gain of 
3.2  8 1.2 mm in the EMD group and of 3.6  8 1.7 mm in 
the GTR group. Histologically, both groups showed heal-
ing, mainly characterized by periodontal regeneration 
 [69] . The mean values of new cementum and PDL fell to 
2.6  8 1.0 and 2.1  8 1.0 mm in the EMD and GTR group, 
respectively. The mean value of new alveolar bone was 0.9 
 8 1.0 mm in the EMD group and 2.1  8 1.0 mm in the 
GTR group. Reparative healing by a long junctional epi-
thelium occurred only in 1 biopsy from the EMD group. 
These results provide evidence that treatment with EMD 
promotes periodontal regeneration in humans and may 
lead to clinical and histological results comparable with 
GTR therapy. These findings are confirmed in subse-
quent reports by others, not only in intrabony but also in 
recession-type defects  [70–75] . Subsequent immunohis-
tological studies have shown that following surgery, EMD 
remains on the root surface for up to 4 weeks and the 
wound healing and/or remodelling process can be fol-
lowed for up to 6 months after treatment with EMD ther-
apy  [76–78] . A very recent human histological study at-
tempted to characterize the tissues developing on the root 
surface at 2–6 weeks following treatment of intrabony de-
fects with EMD  [79, 80] . The results showed that the new-
ly formed tissues on the root surfaces were thick, collag-
enous, devoid of extrinsic fibers and had an irregular sur-
face contour. The presence of electron-dense, organic 
material in the collagenous matrix indicated at least par-
tial mineralization. Embedded cells were numerous and 
the cells on the matrix surface were very large in size. It 
was concluded that following treatment with EMD, a 
bone-like tissue resembling cellular intrinsic fiber ce-
mentum may develop on the root surfaces, instead of 
acellular extrinsic fiber cementum. Furthermore, EMD 
may induce de novo formation of a mineralized connec-
tive tissue on scaled root surfaces and also stimulate ma-
trix deposition on old native cementum. External root 
resorption was observed in 2 cases at 6 and 24 months 
following treatment with EMD, while no periodontal re-
generation was observed when EMD was applied in a 
nonsurgical way into intrabony periodontal defects  [81, 
82] . Based on the available evidence from human histo-
logical studies, it may be concluded that the application 
of EMD in conjunction with periodontal surgery may 
promote formation of new cementum, PDL and bone in 
intrabony and recession defects. Moreover, when applied 
during periodontal surgery EMD can be detected on the 
root surfaces for a period of at least 4 weeks. Based on 
current knowledge, there are no histological data from 
human material evaluating the regenerative potential of 
EMD in furcation defects.
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 Controlled Clinical Studies Evaluating the Effect of 
EMD on Early Wound Healing 
 Several studies have attempted to evaluate the effect of 
EMD treatment on early wound healing  [83–85] . In a 
double-masked, split-mouth, placebo-controlled, ran-
domized study 28 patients with moderately advanced 
chronic periodontitis were scaled and root planed, and 
the soft-tissue wall of the pocket was curetted to remove 
pocket epithelium and adjacent granulation tissue  [83] . 
All experimental sites were carefully irrigated with sa-
line. When the bleeding from the pocket had ceased, a 
24% EDTA gel was applied in the sites and retained for 
2 min. The sites were then thoroughly irrigated with sa-
line to remove EDTA remnants. Subsequently, left and 
right quadrants were randomized to subgingival applica-
tion of EMD (test) or vehicle (control). All sites were re-
examined clinically after 1, 2 and 3 weeks. In addition, a 
visual analogue scale was used to score the degree of post-
treatment discomfort. The results indicated that EMD 
topically applied in instrumented sulci enhanced early 
healing of periodontal soft-tissue wounds. Furthermore, 
at 1 week, the proportion of patients reporting a visual 
analogue scale score  ^  20 was considerably higher for the 
EMD-treated quadrants than for controls. In another 
study, clinical evaluation and patient perception of post-
operative events on the effect of EMD on the healing of 
soft-tissue wounds following periodontal surgery was 
done  [85] . Patients scheduled for periodontal flap surgery 
were treated with either modified Widman flap and ap-
plication of EMD (test) or with modified Widman flap 
alone (control). Clinical measurements were taken at 4 
different points – at surgery and 1, 4 and 8 weeks after 
surgery. Of all parameters evaluated, none showed a sig-
nificant difference between the control and EMD groups, 
except for gingival swelling at the 1-week assessment, 
where the EMD group exhibited a higher swelling score. 
It was concluded that the early wound healing of peri-
odontal flap surgeries in the sites treated with EMD is not 
different from control sites.
 Based on the available data, at the current time it ap-
pears that no definitive conclusions can be drawn regard-
ing the extent to which additional application of EMD 
may further enhance early wound healing following con-
ventional periodontal therapy.
 Controlled Clinical Studies in Intrabony Defects 
 Nonsurgical Periodontal Therapy 
 Two randomized, placebo-controlled clinical studies 
evaluated the effect of EMD as adjunct to nonsurgical 
periodontal therapy in intrabony defects  [86, 87] . Both 
these studies failed to show any significant benefit of us-
ing EMD during nonsurgical periodontal therapy.
 Surgical Periodontal Therapy 
 Side effects, for example incompatibility or allergic re-
actions even after repeated treatment with EMD, were 
not reported in any published studies  [88–91] . A multi-
center study evaluated the potential for sensitization to 
EMD in a subgroup of periodontal patients treated at 
least twice, with an interval of at least 2 months between 
treatments  [91] . Intrabony defects in 376 patients from 11 
university-based postgraduate periodontics programs 
and 5 private practices were treated with open flap de-
bridement, root conditioning with either citric acid 
(pH = 1) or 24% EDTA, followed by defect irrigation with 
sterile saline and application of EMD. The second test 
defect was treated in a similar manner at least 8 weeks 
after the first surgery. No clinical adverse reactions to 
multiple applications of EMD were noted. The results 
demonstrated a lack of clinical adverse reactions follow-
ing 2 separate applications of EMD. Any subjective/ob-
jective adverse reactions experienced by the patient were 
typical complications following routine periodontal sur-
gery and were not directly related to the use of EMD. Data 
from controlled clinical studies have demonstrated that 
treatment of intrabony defects with EMD results in a sig-
nificant reduction of the probing depths and gain of clin-
ical attachment. Moreover, it was shown that EMD at-
tenuated the release of TNF-  and IL-8 in whole blood 
from healthy donors challenged by lipopolysaccharide or 
peptidoglycan, but the release of IL-10 remained un-
changed. EMD also produced a 4-fold increase in the 
cAMP levels of peripheral blood mononuclear cell ly-
sates, which in turn suggested that EMD has anti-inflam-
matory properties  [91] . A randomized, placebo-con-
trolled multicenter study examined the effectiveness of 
EMD in the split-mouth procedure in 33 patients  [92] . 
The results after 36 months showed a mean CAL gain of 
2.2 mm in the test group and of 1.7 mm in the control 
group (open flap debridement). The radiologically deter-
mined bone gain amounted to 2.6 mm in the test group, 
with a 66% fill of the bone defects. However, the control 
teeth did not show any bone gain. In another controlled 
clinical study, Froum et al.  [93] compared the treatment 
D
ow
nl
oa
de
d 
by
: 
R
ad
bo
ud
 U
ni
ve
rs
ite
it 
Ni
jm
eg
en
    
    
    
    
    
    
  
14
9.
12
6.
75
.1
 - 
11
/2
/2
01
5 
12
:2
8:
28
 P
M
 Sculean  /Schwarz  /Becker  /Brecx  
 
Med Princ Pract 2007;16:167–180174
of deep intrabony defects by open flap surgery with and 
without EMD therapy. Twenty-three patients each with 
 6 2 intrabony defects were treated. Thus, a total of 53 de-
fects were treated with open flap surgery + EMD and 31 
with open flap surgery alone. After a healing phase of 12 
months the defects were opened again, to measure the 
defect fill. The results showed that the treatment with 
open flap surgery + EMD resulted in a 3 times larger de-
fect fill than the treatment with flap surgery alone (74% 
defect fill after flap surgery + EMD vs. 23% defect fill af-
ter flap surgery alone)  [93] . In a further prospective, con-
trolled clinical study, a total of 40 patients were treated by 
surgical therapy with either EMD or GTR with a nonbio-
absorbable or with 2 bioabsorbable barriers and com-
pared to open flap surgery (control)  [94] . All 4 regenera-
tive procedures were equally effective regarding probing 
depth, reduction and CAL gain and were significantly 
better than the control treatment. A prospective, ran-
domized, multicenter clinical study reported the treat-
ment of intrabony defects with the papilla preservation 
technique with and without auxiliary application of EMD 
 [95] . From a total of 166 defects, 83 were treated with 
EMD and the remaining 83 acted as control. After 1 year 
the results showed a significantly higher CAL gain in the 
test group than in the control group  [95] . However, a re-
cent randomized, double-masked, placebo-controlled 
clinical trial in 2005 failed to show significant differenc-
es in clinical and radiographic parameters following 
treatment of intrabony defects with open flap debride-
ment and application of EMD or placebo  [96] . Generally, 
most data from controlled clinical studies indicate that 
the additional application of EMD in the context of surgi-
cal therapy of deep intrabony periodontal defects may 
lead to significantly higher gains of clinical attachment 
and defect fill compared to open flap debridement  [92–
95, 97–102] . Surgical treatment with EMD was also dem-
onstrated to significantly improve supracrestal soft-tis-
sue density compared to open flap debridement alone 
 [103, 104] . However, neither postoperative administra-
tion of amoxicillin and metronidazole nor selective cyc-
lo-oxygenase-2 inhibitor appeared to enhance the clini-
cal results  [105, 106] . Furthermore, 2 studies suggested 
that the clinical outcomes of intrabony defects treated 
with EMD do not depend on the use of root conditioning 
of EDTA  [107, 108] . Comparative studies reported similar 
results after treatment of intrabony defects with EMD or 
GTR, whereby the type of GTR barrier (nonbioabsorb-
able or bioabsorbable) did not play a role  [94, 98–101, 109, 
110] . The clinical results are comparable to those after 
GTR therapy. A recent prospective multicenter, random-
ized, controlled clinical trial compared the clinical out-
comes of EMD and GTR with a bioabsorbable membrane 
 [110] . Seventy-five patients with advanced chronic peri-
odontitis were recruited in 7 centers from 3 countries. 
The surgical procedures included access for root instru-
mentation using the simplified papilla preservation flap 
and either the application of EMD or placement of a re-
sorbable GTR membrane. The results of the trial failed to 
demonstrate superiority of 1 treatment over the other. It 
was interesting to note that all cases treated with GTR 
presented at least 1 surgical complication, mostly mem-
brane exposure, while only 6% of EMD-treated sites dis-
played complications.
 The data also indicate that the clinical outcomes after 
treatment of intrabony defects with EMD can be main-
tained over a longer time period (up to 5 years)  [111–
114] .
 Combination Therapies in Intrabony Defects 
 Experimental and clinical studies have indicated that 
the extent of the regeneration is determined by the avail-
able space under the mucoperiosteal flap  [115, 116] . A col-
lapse of the mucoperiosteal flap may limit the area need-
ed for the regeneration process and may thus affect the 
result of the therapy. In order to avoid these disadvan-
tages, combination therapies between EMD and GTR 
and/or EMD and bone substitutes were tested. Histolog-
ical observations, from both man and animals, have dem-
onstrated periodontal regeneration after treatment of in-
trabony defects with some of these combination treat-
ments. In a prospective, controlled, clinical study, the 
treatment of intrabony defects was evaluated following 
treatment with EMD, GTR, combination of EMD + GTR 
and open flap surgery  [99] . It was shown that all 3 regen-
erative treatment procedures resulted in a significantly 
higher improvement of the clinical parameters compared 
to the conventional flap surgery; however, combination 
therapy of EMD + GTR led to no additional improve-
ment. Comparable results were also reported by others 
 [117, 118] . A prospective, controlled split-mouth study in 
11 patients with a total of 12 pairs of intrabony defects 
evaluated the clinical response of EMD with or without 
a combination of a tetracycline-coated expanded polytet-
rafluoroethylene barrier membrane at 6 and 12 months 
following therapy  [118] . At 12 months, the mean CAL 
gain was 1.28  8 2.04 mm in the EMD group and 1.65  8 
1.29 mm in the EMD + GTR group. Except for more post-
operative discomfort at the membrane-treated sites, the 
results failed to reveal any significant differences between 
the 2 groups.
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 Several studies have evaluated the effect of a combina-
tion of EMD and various types of bone graft/bone substi-
tute in the treatment of intrabony defects. Human histo-
logical studies indicate that a combination of EMD and a 
natural bone mineral or bioactive glass may indeed result 
in formation of root cementum, PDL and mineralization 
around the graft particles  [119, 120] . However, the appli-
cation of a natural bone mineral alone also resulted in 
periodontal regeneration  [119] . On the other hand, when 
the defects were filled with a bioactive glass alone, the 
healing was characterized by formation of a long junction 
epithelium and connective tissue encapsulation of the 
graft particles  [120] . Controlled clinical studies compar-
ing treatment of intrabony defects with EMD alone or a 
combination of EMD and different types of bone graft/
bone substitute seem to indicate that the combination of 
EMD and demineralized freeze-dried allogenic bone or a 
natural bone mineral may enhance the clinical outcome 
 [121–124] . However, a recent study comparing the combi-
nation of EMD and a bioactive glass to EMD alone failed 
to show any significant differences between the 2 groups 
 [125] . Furthermore, clinical studies comparing treatment 
with a combination of EMD and a bone graft/bone sub-
stitute to bone graft/bone substitute alone did not dem-
onstrate any advantage of the combination approach 
 [126–128] . Thus, it may be speculated that the type of the 
bone graft/bone substitute and the volume and configu-
ration of the defects are also important factors which 
might influence the clinical outcomes. Further well-de-
signed controlled clinical studies are necessary to evaluate 
the advantage of a combination therapy in relation to the 
single therapies.
 Controlled Clinical Studies in Recession Defects 
 Histological findings in animal and human studies 
have shown that treatment of buccal recession defects 
with a coronally positioned flap and EMD can result not 
only in a covering of the gingival recession but also in the 
formation of cementum, PDL and bone  [56, 58, 62, 63, 67, 
73–75] . In 2 controlled clinical studies, the treatment of 
buccal Miller class I and II gingival recessions with a cor-
onally positioned flap and EMD or coronally positioned 
flap alone were examined using the split-mouth proce-
dure  [129, 130] . Clinical outcome did not show any differ-
ence between the therapies in terms of root coverage over 
a short time period of 1 year. Additional application of 
EMD, however, induced a statistically significantly great-
er formation of keratinized tissue, compared to that with 
coronally positioned flap alone  [130] . A follow-up evalu-
ation of this study showed that over 2 years, complete root 
coverage could be maintained in 53% of the EMD group 
compared to the control (23%)  [131] . However, in the sec-
ond year after therapy as many as 47% of the control group 
had deteriorated compared to only 22% in the treatment 
group.
 Similar results were obtained in a randomized con-
trolled clinical study on 58 contralateral sites, in 17 pa-
tients with  6 2-mm Miller class I, II and III buccal reces-
sions treated with coronally positioned flap and EMD 
(test) or the flap alone (control)  [132] . At 6 months, there 
was a mean increase of keratinized tissue of 0.60 mm for 
the test sites and a mean decrease of 0.05 mm for the con-
trol sites. The test sites demonstrated better root coverage 
(92.9% after 6 months) compared to the control sites 
(66.8% after 6 months)  [132] . These results were recently 
corroborated by others  [133] . In a controlled, clinical, 
split-mouth study involving 17 patients, the therapy of 
buccal Miller class II recessions with a coronally posi-
tioned flap and EMD (test group) or flap alone was com-
pared to connective tissue graft (control)  [134] . A year 
after therapy, the mean value for root coverage was 95.1% 
in the test group and 93.8% in the control group. Total 
root coverage (100%) was reached in 89.5% of the cases in 
the test group and 79% in the control group. Furthermore, 
histological evaluation of 2 biopsies showed that treat-
ment of recession defects with a coronally positioned flap 
and EMD resulted in the formation of root cementum, 
PDL and alveolar bone, while treatment with a coronally 
positioned flap and a connective graft was characterized 
by a long junctional epithelium and even signs of root re-
sorption  [75] . Comparable results were also reported in a 
multicenter, controlled clinical trial comparing the clini-
cal efficacy of a coronally advanced flap procedure with 
the additional use of EMD (test) and subpedicle connec-
tive tissue graft (control)  [135] . At 12 months the root cov-
erage in the test group was 71.7% ( 8 16.14) compared to 
87.0% ( 8 12.22%) of the control. The available data sug-
gest that the use of EMD may enhance the outcome of root 
coverage procedures, but the additional application of a 
connective tissue graft seems to further enhance the for-
mation of keratinized tissue  [134–136] . It is interesting to 
note that most controlled clinical studies evaluating the 
treatment of gingival recessions with coronally reposi-
tioned flaps and EMD therapy reported stable clinical re-
sults after a longer time period, up to 2 years, and an in-
crease in the width of keratinized tissue, thus indicating 
that EMD may have an effect upon the proliferation and 
keratinization of gingival fibroblasts  [131, 137, 138] .
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 Controlled Clinical Studies in Furcation Defects 
 Data from controlled clinical studies evaluating the 
treatment of furcation defects using flap surgery with and 
without EMD are lacking. A multicenter, randomized, 
controlled, split-mouth, clinical study compared the 
treatment of mandibular class II furcation defects with 
EMD or GTR  [139, 140] . A total of 44 patients with 90 
comparable defects on contralateral molars were includ-
ed. Defects were randomly assigned to treatment with 
EMD or GTR with a bioresorbable membrane. Treatment 
effects including gingival margin levels, probing depths, 
bleeding on probing, vertical attachment levels and verti-
cal bone sounding from a stent at 5 buccal sites per tooth 
were evaluated at 8 and 14 months. The results indicated 
that both the treatment modalities led to significant clin-
ical improvements. The median reduction of open hori-
zontal furcation depth was 2.8 mm with the correspond-
ing interquartile interval (1.5–3.5) at the test sites com-
pared with 1.8 mm (1.0–2.8) at the control sites. The 
frequency of complete furcation closure was 8/45 (test) 
and 3/45 (control), partial closure 27/45 in both groups, 
and no change 9/45 and 11/45, respectively. Deterioration 
was observed in 1/45 and 4/45 sites, respectively. The fre-
quency of no pain or no swelling at 1 week after surgery 
was 62 and 44%, respectively, at the test sites and 12 and 
6% at the control sites. It was concluded that there was a 
significantly greater reduction in horizontal furcation 
depth and a comparatively lower incidence of postopera-
tive pain/swelling following EMD compared to GTR 
therapy.
 Conclusions 
 Based on the evidence presented, the following infer-
ences can be drawn.
 • Surgical periodontal treatment of deep intrabony de-
fects with EMD promotes periodontal regeneration. 
The application of EMD in the context of nonsurgical 
periodontal therapy has failed to induce periodontal 
regeneration. 
 • Surgical periodontal therapy of deep intrabony defects 
with EMD may lead to significantly higher improve-
ments in clinical parameters compared to open flap 
debridement alone. The effect of treatment with EMD 
is comparable to that with GTR and can be maintained 
over a 2-year period. 
 • Treatment of intrabony defects with a combination of 
EMD + GTR does not seem to additionally improve 
the outcomes compared to treatment with EMD alone 
or GTR alone. 
 • The combination of EMD and some types of bone 
graft/bone substitute may result in certain improve-
ments in the soft- and hard-tissue parameters com-
pared to treatment with EMD alone. However, further 
studies are needed in order to definitively clarify the 
possible advantage of a combination therapy of EMD 
and bone grafts/bone substitutes in relation to the sin-
gle therapies. 
 • Treatment of recession-type defects with coronally re-
positioned flaps and EMD may promote formation of 
cementum, PDL and bone and may significantly in-
crease the width of the keratinized tissue. 
 • Application of EMD seems to provide better long-
term results than coronally repositioned flaps alone. 
 • Application of EMD may enhance periodontal regen-
eration in manibular class II furcations. The clinical 
results are comparable to those obtained with GTR. 
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